Business Context and Reporting Period
Company: Aziyo Biologics, Inc. (Note: Request metadata listed "Elutia Inc.", but the filing text identifies the registrant as Aziyo Biologics, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: May 9, 2022
Reporting Period: Quarter ended March 31, 2022
Business Context: The Company is an emerging growth company incorporated in Delaware, trading on the Nasdaq Global Market under the symbol "AZYO". This filing announces the issuance of a press release regarding financial results for the quarter ended March 31, 2022.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references a press release (Exhibit 99.1) containing the actual financial data but does not list specific figures within this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Note: Specific financial values are not present in the filing text provided; they are contained in the referenced Exhibit 99.1.
Material Changes
The filing text does not provide specific comparative data or details on material changes versus the prior period. It solely serves to notify investors that results for the quarter ended March 31, 2022, have been announced via a press release.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the full text of the press release is furnished as Exhibit 99.1 and incorporated by reference.
Legal Disclaimer: The information in this Current Report (including Exhibit 99.1) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that Section, nor is it incorporated by reference into other filings except as expressly set forth.
Guidance and Risks: No specific guidance, outlook, or risk factors are detailed in this text segment.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (Press Release dated May 9, 2022), as they are not listed in the 8-K cover page.
- Confirm the company name discrepancy: The request metadata listed "Elutia Inc.", but the filing is for Aziyo Biologics, Inc.
- Review the press release for any updates on clinical trial progress or operational milestones, as this is a biotechnology company.
- Check the "Emerging Growth Company" status implications on financial reporting standards as noted in the filing.